Traders should view this as an expected clinical execution update with no material stock-moving data. The next meaningful catalyst is the preliminary data readout in 2H 2026. Until then, there is no new fundamental information to alter the risk/reward profile.
INKT drugs
INKT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK AT ENTRY AT T+60- T+0 · May 28 $12.20entry
- T+1 · 6mo ago 0.00%α −0.24% · $12.20
- T+5 · 6mo ago +4.59%α +4.64% · $12.76
- T+20 · 5mo ago −4.59%α −1.45% · $11.64
- T+60 · 3mo ago 0.00%α −1.74% · $12.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluating agenT-797 for severe acute lung injury/ARDS. This is a clinical milestone with no revenue or earnings data, and preliminary efficacy readout is not expected until 2H 2026, making the near-term stock impact limited.
Key Facts
- First patient dosed in randomized Phase 2 trial (C-1300-02) for agenT-797 in severe acute lung injury/ARDS patients
- Trial compares agenT-797 + standard of care vs placebo + standard of care; primary endpoints include survival, ventilator-free days, and ICU recovery
- Dosing occurred at First Lviv Territorial Medical Union in Ukraine, with U.S. site expansion underway
- Preliminary data expected in second half of 2026, no near-term catalyst
- agenT-797 is an off-the-shelf allogeneic iNKT cell therapy, delivered without patient-specific manufacturing or HLA matching
- No financial figures, guidance, or material agreements disclosed in the press release
Financial Impact
No revenue, earnings, or financial guidance disclosed, pre-revenue clinical-stage company with $51M market cap
Risk Factors
- Phase 2 trial may fail to meet endpoints, potentially wiping out clinical value of agenT-797 in this indication
- Enrollment in Ukraine faces geopolitical and operational risks
- Pre-revenue company with limited cash runway, future financing risk exists
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302945 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Viewing Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers